Maxim Group initiated coverage of Nutex Health with a rating of Buy and set a new price target of $45.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/12/2024 | $45.00 → $50.00 | Buy | Maxim Group |
| 9/18/2024 | $45.00 | Buy | Maxim Group |
| 2/22/2023 | $3.00 | Outperform | Northland Capital |
8-K - Nutex Health, Inc. (0001479681) (Filer)
8-K - Nutex Health, Inc. (0001479681) (Filer)
Total revenue of $723.6 million for the first nine months of 2025 versus $222.3 million for the first nine months of 2024, an increase of 225.5%Net income attributable to Nutex Health Inc. of $59.0 million for the first nine months of 2025 versus net loss of $9.5 million for the first nine months of 2024, an increase of $68.5 millionDiluted income per share of $8.87 for the first nine months of 2025 versus a loss per share of $1.91 for the first nine months of 2024EBITDA of $142.9 million for the first nine months of 2025 versus $19.9 million for the first nine months of 2024, an increase of 616.4%Adjusted EBITDA of $243.0 million for the first nine months of 2025 versus $16.1 million for th
Total revenue of $455.8 million for the first half of 2025 versus $143.5 million for the first half of 2024, an increase of 217.5%Net income attributable to Nutex Health Inc. of $3.5 million for the first half of 2025 versus net loss of $0.7 million for the first half of 2024, an increase of $4.2 millionDiluted income per share of $0.55 for the first half of 2025 versus a loss per share of $0.15 for the first half of 2024EBITDA of $51.1 million for the first half of 2025 versus $15.6 million for the first half of 2024, an increase of 227.4%Adjusted EBITDA of $144.4 million for the first half of 2025 versus $6.4 million for the first half of 2024, an increase of 2144.2%Net cash from operating
Total revenue of $211.8 million for Q1 2025 versus $67.5 million for Q1 2024, an increase of 214.0%Net income attributable to Nutex Health Inc. of $21.2 million for Q1 2025 versus net loss of $0.4 million for Q1 2024, an increase of $21.6 million.Diluted income per share of $3.33 for Q1 2025 versus a loss per share of $0.08 for Q1 2024EBITDA of $51.5 million for Q1 2025 versus $7.1 million for Q1 2024, an increase of 624.7%Adjusted EBITDA of $72.8 million for Q1 2025 versus $(0.4) million for Q1 2024, an increase of $73.2 millionNet cash from operating activities of $51.0 million for Q1 2025The Company believes its arbitration efforts through the Independent Dispute Resolution (IDR) process
3 - Nutex Health, Inc. (0001479681) (Issuer)
3 - Nutex Health, Inc. (0001479681) (Issuer)
4 - Nutex Health, Inc. (0001479681) (Issuer)
4 - Nutex Health, Inc. (0001479681) (Issuer)
4 - Nutex Health, Inc. (0001479681) (Issuer)
4 - Nutex Health, Inc. (0001479681) (Issuer)
Maxim Group reiterated coverage of Nutex Health with a rating of Buy and set a new price target of $50.00 from $45.00 previously
Maxim Group initiated coverage of Nutex Health with a rating of Buy and set a new price target of $45.00
Northland Capital initiated coverage of Nutex Health with a rating of Outperform and set a new price target of $3.00
HOUSTON, Sept. 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Wesley Bamburg as the Company's Chief Operating Officer, effective October 13, 2025. Mr. Bamburg is an accomplished healthcare executive with 20 years of Fortune 500 experience in healthcare operations, business development, integrated network management, and physician relations. Mr. Bamburg has served as Chief Operating Officer for HCA Houst
HOUSTON, May 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Grant Thornton LLP ("Grant Thornton") as the Company's independent registered public accounting firm to replace CBIZ CPAs ("CBIZ"), effective May 15, 2025. The change of the Company's independent auditor was made after careful consideration and an evaluation process and was approved by the Audit Committee and the Board of Directors of the
HOUSTON, April 22, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 9 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Scott J. Saunders, and Kelvin Spears, MD, to its Board of Directors. They replace John Waters, who recently passed away, and Dr. Daniel Stites, who fulfilled his one-year term Board commitment. The Board has determined that Mr. Saunders satisfies the current independent director standards established by the rules of The Nasdaq Stock Market. Mr. Saunders will s
Total revenue of $723.6 million for the first nine months of 2025 versus $222.3 million for the first nine months of 2024, an increase of 225.5%Net income attributable to Nutex Health Inc. of $59.0 million for the first nine months of 2025 versus net loss of $9.5 million for the first nine months of 2024, an increase of $68.5 millionDiluted income per share of $8.87 for the first nine months of 2025 versus a loss per share of $1.91 for the first nine months of 2024EBITDA of $142.9 million for the first nine months of 2025 versus $19.9 million for the first nine months of 2024, an increase of 616.4%Adjusted EBITDA of $243.0 million for the first nine months of 2025 versus $16.1 million for th
HOUSTON, Aug. 20, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments in 11 states and primary care-centric, risk-bearing physician networks, today disclosed non-reliance on its (i) unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2025 contained in the Form 10-Q for the period ended March 31, 2025 (the "Original Form 10-Q") and its (ii) audited consolidated financial statements as of and for the years ended December 31, 2024 and 2023 contained in the Form 10-K for the
HOUSTON, Aug. 14, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will delay filing its Form 10-Q for the period ending June 30, 2025 due to non-cash accounting adjustments related to the treatment of stock based compensation obligations for certain under-construction and ramping hospitals, as disclosed in previous filings. The Company additionally provided preliminary financial results for the three and six months ended
SC 13G - Nutex Health, Inc. (0001479681) (Subject)
SC 13G/A - Nutex Health, Inc. (0001479681) (Subject)
SC 13G - Nutex Health, Inc. (0001479681) (Subject)